Loading clinical trials...
Loading clinical trials...
A Phase Ⅰb Study Evaluating the Safety, Tolerability and Pharmacokinetics of Pegylated Recombinant Human Endostatin (PEG-ENDO) in Subjects With Advanced / Metastatic Non-small Cell Lung Cancer (NSCLC) or Other Solid Tumors
Conditions
Interventions
Pegylated Recombinant Human Endostatin（PEG-ENDO）
Locations
2
China
Beijing Hospital
Beijing, Beijing Municipality, China
Tianjin medical university cancer institute&hospital
Tianjin, Tianjin Municipality, China
Start Date
April 2, 2020
Primary Completion Date
May 31, 2021
Completion Date
September 30, 2021
Last Updated
June 2, 2020
NCT06305754
NCT07486219
NCT06898450
NCT05720117
NCT06658951
NCT06625775
Lead Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions